...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases
【24h】

Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases

机译：肠道免疫和肠道菌群作为预防动脉粥样硬化性心血管疾病的治疗目标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atherosclerosis is considered a chronic inflammatory disease and an intervention targeting the inflammatory process could be a new therapeutic strategy for preventing atherosclerotic cardiovascular diseases (CVD). We hypothesized that the intestine, which is considered the biggest immune organ in the human body, could be a therapeutic target for preventing CVD. We demonstrated that oral administration of anti-CD3 antibody or an active form of vitamin D-3 reduced atherosclerosis in mice via induction of regulatory T cells and tolerogenic dendritic cells in the gut-associated lymphoid tissues. Similar to regulatory immune responses achieved by oral tolerance, our method had systemic effects that ultimately contributed towards atherosclerosis reduction. Recently, we have been interested in the gut microbiota, which have been reported as highly associated with intestinal immunity and systemic metabolic disorders, including obesity and diabetes. Notably, the guts of obese individuals are predominantly colonized by Firmicutes over Bacteroidetes. The association between atherosclerosis and microbiota has been attracting increased attention, and gut microbiota have been shown to participate in the metabolism of a proatherogenic compound called trimethylamine-N-oxide (TMAO) and aggravate CVD. Our investigation of the relationship between susceptibility to CVD and the gut microbiota revealed a characteristic flora type. Here, we discuss the evidence for the relationship between the gut microbiota and cardiometabolic diseases, and consider the gut microbiota as new potential therapeutic targets for treating CVD.
机译：动脉粥样硬化被认为​​是一种慢性炎症性疾病，针对炎症过程的干预措施可能是预防动脉粥样硬化性心血管疾病（CVD）的新治疗策略。我们假设肠道被认为是人体最大的免疫器官，可以作为预防CVD的治疗靶标。我们证明口服抗CD3抗体或活性形式的维生素D-3可通过诱导肠道相关淋巴组织中的调节性T细胞和致耐受性树突状细胞减少小鼠的动脉粥样硬化。与通过口服耐受获得的调节性免疫反应相似，我们的方法具有全身作用，最终有助于减少动脉粥样硬化。最近，我们对肠道菌群产生了兴趣，据报道，肠道菌群与肠道免疫力和全身代谢异常（包括肥胖症和糖尿病）高度相关。值得注意的是，肥胖个体的内脏主要由坚韧菌定居于拟杆菌。动脉粥样硬化与微生物群之间的联系已引起越来越多的关注，并且肠道微生物群已显示出参与称为三甲胺-N-氧化物（TMAO）的促动脉粥样硬化化合物的代谢并加剧了CVD。我们对CVD易感性与肠道菌群之间关系的研究揭示了特征菌群类型。在这里，我们讨论了肠道菌群与心脏代谢疾病之间关系的证据，并将肠道菌群作为治疗CVD的新潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号